



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION



BBT594

Item No. 41359

CAS Registry No.: 882405-89-2

Formal Name: 5-[[6-(acetylamino)-4-pyrimidinyl]oxy]-2,3-dihydro-N-[[4-(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-1H-indole-1-carboxamide

Synonym: NVP-BBT594

MF: $C_{28}H_{30}F_3N_7O_3$


FW: 569.6

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BBT594 is supplied as a solid. A stock solution may be made by dissolving the BBT594 in the solvent of choice, which should be purged with an inert gas. BBT594 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

BBT594 is an inhibitor of Bcr-Abl^{T315I} ($\text{IC}_{50} = 44 \text{ nM}$), a form of the Bcr-Abl fusion protein containing a tyrosine-to-isoleucine substitution at position 315.¹ It decreases proliferation in mouse Ba/F3 hematopoietic cells expressing Bcr-Abl^{T315I} ($\text{GI}_{50} = 117 \text{ nM}$). BBT594 (1 or 5 μM) also inhibits phosphorylation of Jak2 and Stat5 in Ba/F3 cells.²

References

1. Manley, P.W., Brügger, J., Floersheimer, A., *et al.* Rational design of T315I BCR-abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463. *Med. Chem.* **62(7/8)**, 579 (2008).
2. Andraos, R., Qian, Z., Bonenfant, D., *et al.* Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. *Cancer Discov.* **2(6)**, 512-523 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/27/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM